Precision BioSciences Inc (DTIL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Precision BioSciences Inc stock (DTIL) is currently trading at $6.40. Precision BioSciences Inc PS ratio (Price-to-Sales) is 4.71. Analyst consensus price target for DTIL is $32.00. WallStSmart rates DTIL as Underperform.
- DTIL PE ratio analysis and historical PE chart
- DTIL PS ratio (Price-to-Sales) history and trend
- DTIL intrinsic value — DCF, Graham Number, EPV models
- DTIL stock price prediction 2025 2026 2027 2028 2029 2030
- DTIL fair value vs current price
- DTIL insider transactions and insider buying
- Is DTIL undervalued or overvalued?
- Precision BioSciences Inc financial analysis — revenue, earnings, cash flow
- DTIL Piotroski F-Score and Altman Z-Score
- DTIL analyst price target and Smart Rating
Precision BioSciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Precision BioSciences Inc (DTIL) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Precision BioSciences Inc (DTIL) Key Strengths (4)
Keeps $37 of every $100 in revenue after operating costs
Revenue surging 5261.00% year-over-year
Trading at 1.75x book value, attractively priced
64.15% held by institutions, strong professional interest
Supporting Valuation Data
Precision BioSciences Inc (DTIL) Areas to Watch (4)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 4.7x annual revenue
Precision BioSciences Inc (DTIL) Detailed Analysis Report
Overall Assessment
This company scores 43/100 in our Smart Analysis, earning a D grade. Out of 8 metrics analyzed, 4 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.75) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 36.60%. Growth metrics are encouraging with Revenue Growth at 5261.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Market Cap. Some valuation metrics including Price/Sales (4.71) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -62.70%, Profit Margin at -133.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -62.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 5261.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DTIL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DTIL's Price-to-Sales ratio of 4.71x trades at a deep discount to its historical average of 13.21x (51th percentile). The current valuation is 97% below its historical high of 184.5x set in Mar 2026, and 2514% above its historical low of 0.18x in Jan 2024. Over the past 12 months, the PS ratio has expanded from ~1.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Precision BioSciences Inc (DTIL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Precision BioSciences Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 34M with 5261% growth year-over-year. The company is currently unprofitable, posting a -133.5% profit margin.
Key Findings
Revenue growing at 5261% YoY, reaching 34M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 42% of revenue (14M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -133.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Precision BioSciences Inc maintain 5261%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Precision BioSciences Inc.
Bottom Line
Precision BioSciences Inc is a high-conviction growth story with revenue accelerating at 5261% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -133.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(40 last 3 months)
| Insider | Type | Shares |
|---|---|---|
AMOROSO, MICHAEL Director, President and CEO | Sell | -34,799 |
Data sourced from SEC Form 4 filings
Last updated: 8:23:08 AM
About Precision BioSciences Inc(DTIL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.